Clinical Trial

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Name: AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC — clinical trial record (NCT05247684)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC

Protocol Amendment History 2 changes

critical Primary endpoint(s) modified 2026-07-30

minor Completion pushed: 2026-12-31 -> 2027-12-31 2026-07-30

Trial Details

NCT Number	NCT05247684
Lead Sponsor	Akeso
Conditions	Resectable Non-small Cell Lung Cancer
Enrollment	90 participants
Start Date	2022-02-20
Primary Completion	2025-08-18 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-29